Expression of vascular endothelial growth factor and its receptors VEGFR-1 and 2 in gastrointestinal stromal tumors, leiomyomas and schwannomas

Table 1 Immunohistochemistry of VEGF pathway components in intestinal stromal tumours, n (%)

	n	VEGF		VEGFR-1		VEGFR-2
		-	+	-	+	-	+
GISTs	33	7 (21.2)	26 (78.8)	9 (27.3)	24 (72.7)	3 (9.1)	30 (90.9) b
Leiomyoma	15	6 (40.0)	9 (60.0)	3 (20.0)	12 (80.0)	10 (66.7)	5 (33.3)
Schwannoma	6	3 (50.0)	3 (50.0)	2 (33.3)	4 (66.7)	2 (33.3)	4 (66.7)

^bP < 0.0001 vs leiomyomas.

Table 2 VEGF, VEGFR-1 and 2 expression and categories for GISTs (n = 33) n (%)

Total	n	VEGF		VEGFR-1		VEGFR-2
		-	+	-	+	-	+
	33	7	26	9	24	3	30
Risk categories		NS		NS		NS
High	4	0 (0.0)	4 (100)	0 (0.0)	4 (100)	0 (0.0)	4 (100)
Intermediate	5	1 (20.0)	4 (80.0)	2 (40.0)	3 (60.0)	0 (0.0)	5 (100)
Low	17	3 (17.6)	14 (82.4)	5 (29.4)	12 (70.6)	2 (11.8)	15 (88.2)
Very low	7	3 (42.9)	4 (57.1)	2 (28.6)	5 (71.4)	1 (14.3)	6 (85.7)
Mitosis counts (per 50 fields, HPF)		NS		NS		NS
< 2	17	4 (23.5)	13 (76.5)	6 (35.3)	11 (64.7)	2 (11.8)	15 (88.2)
2-5	8	2 (25.0)	6 (75.0)	3 (37.5)	5 (62.5)	1 (12.5)	7 (87.5)
6-10	4	1 (25.0)	3 (75.0)	0 (0.0)	4 (100)	0 (0.0)	4 (100)
>10	4	0 (0.0)	4 (100)	0 (0.0)	4 (100)	0 (0.0)	4 (100)
Tumour size (cm in length)		NS		NS		NS
< 2	6	3 (50.0)	3 (50.0)	2 (33.3)	4 (66.7)	1 (16.7)	5 (83.3)
2-< 5	20	3 (15.0)	17 (85.0)	5 (25.0)	15 (75.0)	2 (10.0)	18 (90.0)
5-< 10	6	1 (16.7)	5 (83.3)	2 (33.3)	4 (66.7)	0 (0.0)	6 (100)
> 10	1	0 (0.0)	1 (100)	0 (0.0)	1 (100)	0 (0.0)	1 (100)

NS: Not significant.